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1. Introduction 
Cancer is one of the most lethal diseases in the world. Traditional methods for cancer 
treatment are surgery, chemotherapy and radiotherapy. Early stage cancer patients may be 
cured by radical surgery and (or) chem(radio-)therapy. However, advanced cancer patients 
usually suffer from chem(radio-)resistance or metastasis, most of which can not be 
controlled by current therapy. Furthermore, traditional chem(radio-)therapy will bring 
patients with severe side effects as they not only kill cancer cells, but also normal cells.  
Many investigators believe the potential to make great progress in cancer treatment lies in 
understanding the molecular biology of cancer and exploiting effective agents targeting 
abnormal molecules which regulate the growth and metastasis of tumor (Ku and Ilson, 
2010). This is called targeting therapy, which can selectively kill cancer cells with minor side 
effects. Effective targeting therapy lies on good targets chosen and the methods used to 
deliver targets into the tumor mass safely and efficiently. During the past decades, various 
important tumor targets were exploited. 
2. Targeting tumors by dysfunctional pathways 
Overexpression of receptors and the abnormal activation of intracellular kinase mutations, 
resulting downstream of signaling pathways enhanced, leading to cell transformation, 
proliferation, resistance to apoptosis and eventually promote tumorigenesis. Therefore, 
signaling pathway has become a potential therapeutic target for cancer. 
2.1 Targeting the EGFR signaling pathway 
EGFR pathway mediates many important physiological processes in both normal and 
cancerous cells. Because of the function of the EGFR pathway, a number of therapeutic 
agents have been developed aiming to target EGFR. To date, five EGFR-targeted agents 
have been approved by the FDA for treating cancer patients. Erlotinib (OSI-774, Tarceva) 
was approved to treat metastatic non-small cell lung cancer (NSCLC) as single agent and to 
be used in combination with gemcitabine for pancreatic cancer. Another small molecule 
EGFR kinase inhibitor, Gefitinib (ZD1839, Iressa), is being used for locally advanced and 
metastatic NSCLC (Lo). Lapatinib (GW572016, Tykerb/Tyverb) is an EGFR/HER2-dual 
www.intechopen.com
 
Targets in Gene Therapy 
 
170 
targeting small molecule inhibitor, it used in combination with other drugs, for patients 
with advanced or metastatic breast cancer whose cancer is HER2 positive and has failed to 
respond to other drugs (Moy et al., 2007).  
2.2 Targeting the NF-κB pathway  
Many cancer cells show aberrant or constitutive NF-κB activation which mediates resistance 
to chemo- and radio-therapy. Based on the pivotal role of the NF-κB pathway in the tumor 
progression, the NF-κB signaling pathway has become a potential target for 
pharmacological intervention. Strategies for blocking NF-κB include a NF-κB targeting 
strategy and an upstream strategy. The NF-κB targeting strategy involves blocking the 
activation of NF-κB signaling pathway, includes: (a) glucocorticoids used to block the 
transactivation of NF-κB (D'Acquisto et al., 1998). (b) decoy oligodeoxynucleotides (ODNs) 
used to block the DNA binding of NF-κB (Karin et al., 2004). On the other hand, the 
upstream strategy includes: (a) IKK inhibitors NSAIDs, sulfasalazine, arsenic trioxide, 
curcumin, thalidomide; (b) proteasome inhibitors PS-341, MG132; (c) the recombinant 
adenovirus-mediated overexpression of the IκBǂ gene. (d) cell-permeable peptides SN-50; 
(e) antioxidants disulfiram, glutathione (Chen et al., 2002; Tomita et al., 2003). 
2.3 Targeting the PTEN/PI3K/AKT signaling pathway  
PTEN/PI3K/AKT constitutes an important pathway regulating the signaling of cell 
proliferation, survival, apoptosis, and metabolism. Many components of this pathway have 
been described as causal forces in cancer. Once the activity of mTOR induced by disfunction 
of PTEN/PI3K/AKT pathway, the promotion of tumor proliferation and growth are 
achieved through its downstream targets. A number of basic research studies and clinical 
trials have investigated that rapamycin, the potential of the selective mTOR inhibitor could 
inhibit activity of both mTOR and AKT, suggesting that it may be an effective therapeutic 
blockade of PI3K signaling (Guertin and Sabatini, 2007). PI3K inhibitors, TGX115, LY294002 
derivatives have shown to have greater solubility, lower toxicity, improved 
pharmacodynamics, and more specific PI3K selectivity than LY294002 (Granville et al., 
2006). In addition, PX-866a, wortmannin derivative has more potent and less toxic effects 
than wortmannin (Jiang and Liu, 2008). SF1126 is a small molecule inhibitor that can inhibit 
all isoforms of PI3K class. In preclinical studies, it has been identified to be effective for 
tumor treatment in a variety of mouse tumor models, including prostate, breast, lung, 
multiple myeloma, and other cancers (Hennessy et al., 2005). Lipid-based inhibitors of Akt 
were the first group of inhibitors to be developed. Perifosine is the best-characterized Akt 
inhibitor, which inhibits the translocation of Akt to the cell membrane. It can inhibit the cell 
growth in different solid tumors (Martelli et al., 2003). Several other Akt inhibitors such as 
the indazole-pyri-dine A-443654 and 9-methoxy-2-methylellipticinium acetate (API-59-OMe) 
have been identified. A-443654 was shown to increase the effect of paclitaxel treatment both 
in vitro and in vivo (Han et al., 2007). API-59-OMe can inhibit cell growth and induce 
apoptosis of several different human cancer cells, including prostate, breast, endometrial 
and ovarian cancers (Jin et al., 2004; Tang et al., 2006). 
2.4 Targeting the MAPK signaling pathway  
The RAS–mitogen activated protein kinase (MAPK) signaling pathway not only promotes 
cell proliferation, but also mediates cell survival. The activity of this pathway was reported 
to be upregulated in a broad spectrum of human tumors. In this signalling pathway, RAS, 
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RAF and MEK proteins have unique features that make it a good therapeutic target. By 
inhibiting the post-translational addition of farnesyl group to RAS by farnesyltransferase, it 
was thought that Farnesyltransferase inhibitors (FTIs)would be able to target human tumors 
in which RAS was constitutively activated (Sebolt-Leopold and Herrera, 2004). Several FTIs 
such as BMS-214662, Sarasar and Zarnestra have been studied in patients diagnosed with a 
range of cancers. FTIs could be specific and effective therapeutic agents, however, clinical 
data obtained so far leads us to conclude that these agents do not represent a viable 
approach to blocking signal transduction through the RAS–MAPK pathway. Therefore, 
several small molecule RAF inhibitors have now been reported. According to published 
reports, only BAY 43-9006 has reached the clinical testing stage. It has completed Phase I 
and Phase II trials. It has been reported that this agent is generally well tolerated. However, 
the toxicities involving the gastrointestinal track and the skin have existed. Phase III trials to 
be focusing on patients with renal-cell carcinoma indicated that BAY 43-9006 lack of 
specificity. So, although BAY 43-9006 has promise as an anticancer agent, it is difficult to 
assess the impact of RAF inhibition on observed clinical outcomes. The first MEK inhibitor 
reported to inhibit tumor growth in vivo was CI-1040 (Sebolt-Leopold et al., 1999). There was 
evidence of antitumor activity in the Phase I trial, however, similar results were not 
observed in Phase II trials, so PD0325901, which is structurally highly similar to CI-1040, 
was subsequently developed. The anticancer activity of PD0325901 was improved compared 
with CI-1040. The longer duration and greater solubility leading to improved bioavailability, 
and increased metabolic stability. Therefore, PD0325901 viewed as a significantly more 
potent MEK inhibitor (Sebolt-Leopold and Herrera, 2004).  
 
 
Fig. 1. Targeting the PTEN/PI3K/AKT and MAPK signaling pathway 
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3. Targeting tumors with tumor suppress gene p53 
Clinical studies have shown that p53 is a tumor suppressor which mutates in about 50% of 
human cancers, and where the gene itself is not mutated, its signal pathway functionally 
inactivated. Three decades of researches in p53 have reached an understanding of p53 
playing a key role in the regulations of many different genes in response to a wide variety of 
epigenetic stresses.  
3.1 Regulation of p53 expression 
In normal cells, p53 restrains its expression and function to maintain normal homeostasis. 
Critical for the control of p53 function are its two main negative regulators: Mdm2 and 
Mdmx. Duplicated from a single ancestral gene, Mdm2 and Mdmx have similar sequences. 
They bind to p53 via an N-terminal hydrophobic pocket, thus inhibiting transactivation 
function of p53 (Kruse and Gu, 2009). The C-terminal of both Mdm2 and Mdmx contain a 
RING domain which has intrinsic E3 ubiquitin ligase activity and it targets p53 for 
ubiquitin-dependent degradation by proteasome both in nucleus and cytoplasm (Deshaies 
and Joazeiro, 2009). Mdm2 and Mdmx also induce the exportation of p53 from the nucleus 
to the cytoplasm. Thus, these two proteins negatively regulate p53 by both suppression of 
transactivation and post-translational destabilization.  
 
 
Fig. 2. Targeting tumors with tumor suppress gene p53 
3.2 Conformation of p53 
The p53 protein contains three main functional domains: N-terminal harbors transcriptional 
activation domain 1 (TAD1, residues 20-40), TAD2 (residues 40-60) which interacts with 
Mdm2 and Mdmx, and the proline domain (PP, residues 60-90); in the middle lies the 
central core sequence-specific DNA-binding domain (DAD, residues 100-300), it interacts 
with its target genes or proteins; and C-terminal contains the tetramerization domain (Tet, 
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residues 325-356) and lysine-rich basic C-terminal domain (++, residues 363-393) which 
regulates DNA-binding. Interacts mainly with sequence-specific DNA binding sites of its 
target agents, p53 starts series of cellular responses: cell-cycle arrest, apoptosis, DNA-repair 
and so on. For example, Brn3A and Hzf with DAD, C-Abl with Tet, YB1 and p18/Hamlet 
with ++ selectively induce p53 activation of cell-cycle arrest genes like p21. Conversely, 
ASPPs with DAD and Brn3b, and so on with the p53 C-terminal selectively induce apoptotic 
genes like PUMA and Bax (Vousden and Prives, 2009). 
3.3 Function of p53 
Here comes to questions: When do cells perform cell-cycle arrest, and when do they bring 
about senescence and apoptosis? Some researches hypothesis that the outcome of p53 
activation mostly depends on the type of tissue and stress, how severe the stress is, the 
microenvironment, and the post-transcriptional modification. With mild impact to DNA, 
p53 may stabilize the genes, including DNA repair and activating anti-oxidant genes. As a 
result, p53 acts as a protector by preventing the generation of oncogenic lesions. Conversely, 
once severe stress happens, like oncogene activation, lethal DNA damage or hypoxia, p53 
may start senescence and apoptosis, eliminating badly injured cells which cannot be rescued 
by cell-cycle arrest (Vousden and Lu, 2002).  
3.4 Wild-type p53 in cancers 
In tumors which have wild-type p53 reduced, disturbing the interaction between p53 and 
Mdm2/Mdmx may rationally restore p53 function and may enhance sensitivity of tumors to 
chemotherapy and radiotherapy.  
Nutlins, a well studied inhibitor family of the Mdm2-p53 complex, are highly selective for 
Mdm2 and they can tightly bind to their receptors (Dickens et al.). In the Nutlin family there 
is Nutlin-3, it competes for binding to Mdm2, so displaces p53 protein and releases it to 
function normally in cancer cells derived from hematologic malignancies (Secchiero et al., 
2008). The molecular pathways in the Nutlin-3 induced responses still wait to be explored. 
A small molecular compound, RITA, induces wild-type p53 activation and accumulation 
thus programs apoptosis in different tumor cell lines of colon, lung, breast, etc both in vitro 
and in vivo. It prevents interaction between p53 and Mdm2 through binding to the 1-63 
residues of the p53 protein N-terminal (Issaeva et al., 2004).  
3.5 Mutant p53 in cancers 
A large-scale sequencing of various tumor cells proved that p53 mutations, mostly DNA 
binding domain mutations are common events.  
Small molecular compounds for mutant p53 reactivation via different mechanisms have 
been identified in recent years. CP-31398, stabilizes the conformation of DNA binding 
domain to restore the function of several p53 mutants. Foster. et al reported that CP-31398 
suppressed the growth of both human tumor cells in vitro and xenograft tumors in mice 
(Foster et al., 1999).  
Similar with CP-31398, PRIMA-1 also serves to suppress tumor cell growth by reactivating 
the transcriptional function of mutant p53 and inducing cofactors responsible in p53-
mediated apoptosis like PUMA, Noxa, and Bax, which induce caspase activation, especially 
caspase-2 (Bykov et al., 2002). Rescue tumor suppression function of p53 will pave the way 
for future anti-cancer therapy. 
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For the purpose of inducing p53 activities in a desirable way, a wide range of unknown 
fields from the p53 posttranscriptional modifications, cofactors to network of targeted 
agents wait to be fetched. 
4. Targeting tumors by anti-angiogenesis 
Cytotoxic approaches to killing tumor cells, based on their increased rate of proliferation 
relative to normal cells, have been the mainstay of cancer therapy for decades. However, 
over 30 years ago, as proposed by Folkman in 1971, angiogenesis is required for tumor, so 
targeting angiogenesis is a significant approach in inhibiting solid tumor growth and hence, 
limit cancer progression (Folkman, 1971).  
Angiogenesis is the formation of new blood vessels from pre-existing ones. The 
understanding of the angiogenic mechanisms and the successful use of several angiogenesis 
inhibitors in animal models, have led to clinical applications of anti-angiogenic therapy. This 
strategy has several advantages over traditional chemotherapy, in principle, including side 
effects and less toxicity, a reduced risk for development of resistance, and a general broad 
spectrum of activity. More important, anti-angiogenic approaches can efficiently target both 
low and high proliferating tumor cells, so unlike conventional cytotoxic chemotherapies that 
are more effective against fast growing tumors, anti-angiogenic therapy could act against a 
broader range of cancers. The expected results are different from traditional cancer 
therapies, the first aim of anti angiogenesis is to stabilize the disease rather than to eradicate 
the tumor mass, unlike radiotherapy or chemotherapy; however these strategy can be used 
in concert (Bisacchi et al., 2003). 
4.1 Potential anti-angiogenic factors for gene therapy 
Induction of the angiogenic switch depends on a local change in the balance between 
inhibitors and activators of angiogenesis. The switch to an angiogenic phenotype of tumor 
requires downregulation of angiogenesis inhibitors and upregulation of  angiogenic factors 
(Dell'Eva et al., 2002). Until now, many angiogenic peptides have been identified, including 
vascular endothelial growth factor (VEGF) and vascular permeability factor (VPF), basic and 
acidic fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived 
epidermal cell growth factor (PD-ECGF), platelet-derived growth factor (PDGF), insulin-like 
growth factors (IGFs), interleukin-8 (IL-8),transforming growth factor-ǂ and ǃ (TGF-ǂ and -
ǃ), heparin growth factor, granulocyte colony stimulating factor, E-selectin, angiogenin, 
tumor necrosis factor-ǂ (TNF-ǂ). Angiogenic factors released by tumor cells stimulate 
endothelial cells (EC) which become activated, providing growth factors (FGF-1,-2) and 
matrix metalloproteinases (MMPs). Proteolytic activities of the MMPs degrade the 
surrounding tissue and vascular membrane, leading to EC proliferation, migration and new 
capillary formation. 
Thus, the goal of anti-angiogenic gene therapy is to switch the local balance between 
angiogenic factors and angiogenic inhibitors in tumor microenvironment to the anti-
angiogenic phenotype, targeting one or more events of angiogenesis cascade. The more 
attractive angiosuppressive factors for clinical trials are: naturally occurring inhibitors of 
angiogenesis, agents that interfere with vascular basement membrane and extracellular 
matrix MMP inhibitors, angiostatic steroids and others, anti-adhesion molecules antibodies 
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and miscelllaneous drugs that modulate angiogenesis by diverse mechanisms of action 
(O'Reilly et al., 1997).  
4.2 Clinical trials targeting tumor angiogenesis 
The greatest clinical success with the antiangiogenic strategy to date, has been achieved with 
bevacizumab, the antibody to VEGF. Bevacizumab blocks the binding of VEGF-A to its 
receptors, VEGFR-1 and VEGFR-2. In rectal cancer patients, this VEGF signaling inhibitor 
reduced tumor microvessel density, blood flow and interstitial pressure, and increased the 
percentage of vessels covered by pericytes (Willett et al., 2004). 
Endostatin is a 20-kDa proteolytic COOH-terminal fragment derived from collagen XVIII58. 
Endostatin reduces endothelial cell proliferation and migration, significantly reduces 
invasion of endothelial as well as tumor cells into the reconstituted basement membrane and 
acts as a potent inhibitor of angiogenesis and tumor growth. In preclinical studies, 
expression of endostatin decreased tumor vascularization 3-fold with a concomitant 3-fold 
increase in the number of apoptotic cells. Endostatin is the first endogenous angiogenesis 
inhibitor to enter clinical trials. The earliest phase Ⅰ trials were published in 2002 and 2003 
at The University of Texas M.D. Anderson Cancer Center. The final results show that the 
anti-angiogenic drug was safe and reduced blood flow in patients. There was some 
shrinkage of tumors among the participants, and two patients showed encouraging results 
(Thomas et al., 2003). A Chinese phase Ⅲ trial using recombinant endostatin in combination 
with chemotherapy in NSCLC has exhibited a significant increase in response rates and time 
to progression. Another potent angiogenesis inhibitor is angiostatin (38kDa), which is 
generated as a result of proteolytic cleavage of plasminogen and comprises the first four 
triple loop disulphide-linked structures of plasminogen, termed kringle domains (O'Reilly et 
al., 1994). Currently, phase II/III clinical trials of endostatin and angiostatin are ongoing, 
and preliminary data analysis show minimal toxicities but anti-tumor results are 
inconsistent.  
Now, more than 300 anti-angiogenic molecules targeting different signalling pathways and 
over 20 angiogenic growth factors are being tested for their potential anti-cancer efficacies at 
preclinical and clinical stages. Eight new drugs in which anti-angiogenic activity is 
considered to be central to their therapeutic effects have been approved by the FDA in the 
United States for the treatment of cancer (Table 1) (Park and Dilda).   
4.3 Perspectives 
Antiangiogenic methods have changed the landscape in traditional cancer therapy after the 
initial clinical success of bevacizumab in 2004. Future development of antiangiogenic drugs 
targeting various pathways with different principles, particularly in combination therapy 
settings, is expected to significantly improve therapeutic efficacies. One of the important 
approaches of increasing therapeutic efficacy is to optimize the drug delivery systems that 
enable accurate drug release only in malignant tissues, persistent release and tightly 
controlled release of antiangiogenic agents. Long-term delivery is particularly advantageous 
for clinical benefits as withdrawal of these drugs might cause a rebound angiogenic activity 
in tumors. However, persistent release of the same drug in cancer patients might elicit 
evasive refractoriness to antiangiogenic therapy. This dilemma may be resolved using a 
smart microchip delivery system that simultaneously or sequentially releases multiple drugs 
targeting different pathways. 
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Non-small cell lung carcinoma, 
metastatic colorectal cancer and 
breastcancer 
Cetuximab/Erbitux (Bristol-
Myers Squibb ImClone) 
EGFR 
 
Metastatic colorectal carcinoma and 




Metastatic colorectal carcinoma 
 
Erlotinib/Tarceva (Genentech 
OSI  Roche) 
EGFR 














Advanced renal cell carcinoma and 
advanced hepatocellular carcinoma 
Table 1. Anti-angiogenic therapeutics FDA approved for the treatment of cancer. 
 
 
Fig. 3. Targeting tumor by antiangiogenesis 
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5. Targeting tumors with monocloning antibody  
For several decades, antibodies has been hoped to become a ‘magic bullets’ to cure patients, 
and this vision came true with the development of hybridoma technology by Kohler and 
Milstein (Kohler and Milstein, 1975). The antibodies are Y-shaped proteins with two 
identical light chains and two identical heavy chains. The arms of the Y identify antigens, 
and the stem of Y alerts and recruits the components to attack the molecular targets once 
bounded.  
Present, more than 400 mAbs entered commercial clinical development and anticancer 
mAbs comprised almost half of the total mAbs (Reichert et al., 2005).  To date, a dozen of 
anticancer mAbs have been approved for marketing by FDA. There are two modes that 
mAbs destroy the target tumor cells, one is direct way by conjugating radioactive toxins or 
triggering apoptosis. Another is the indirect way through activating immune system 
components or blockade of critical receptors.  
The conjugated mAbs can increase the specificity of chemo- or radiation therapy. Drugs 
composed of the conjugate can be produced by chemical linkers, while the proteins can be 
produced by either chemosynthesis or genetic engineering. However, some challenges exist 
in the development of immunotoxins since the protein toxins can lead to immunogenic 
action in human and the drug toxins which may lack potency for the little doses degrade in 
the way to the tumor site. Another limitation is that immunotoxins require internalization to 
gain a cytotoxic effect on tumor cells. 
In the recent data, over half of the mAbs are unmodified mAbs. The characteristics like 
average half-life, vary with the isotype of the unmodified mAbs are determined to be the 
crystallizablefragment (Fc) region. A common mode of mAbs function is to activate the 
components of the human immune system attacking the target cancer cells. Once binding to  
target, mAbs can call up effector cells to activate the complement. These actions are known 
as antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity 
(CDC), and they are mediated by the Fc portion of mAbs. 
5.1 Targets in solid tumors  
EGFR family includes EGFR(c-erbB-1), HER2/neu (c-erbB-2), HER3(c-erbB-3), and HER4 (c-
erbB-4). EGFR overexpressed in many solid tumors, such as non-small cell lung cancer, 
colorectal cancer, breast cancer, head and neck cancer, and prostate cancer. Some anti-EGFR 
mAbs can inhibit tumor cell growth and activate tyrosine kinases. Cetuximab, a chimeric 
form of anti-EGFR antibody can objective anti-tumor responses alone, or in combination 
with other treatment strategies for the overexpressing EGFR cancers. A second EGFR-
targeted mAbs, Panitumumab, was produced in a muse while the genes of antibody came 
from human (Mendez et al., 1997).  
bold (HER2/neu) is overexpressed in 25% of breast cancer cells, and in other 
adenocarcinomas of the ovary, lung, prostate and gastrointestinal tract (Baselga et al., 1996). 
Trastuzumab is a humanized mAb that derived from the murine mAb4D5, which combined 
with chemotherapy in the randomized phase 3 trial shows a 25% increase in survival after 
29 months than chemotherapy alone. It had also been shown activity in Trastuzumab 
combination with small- molecule drugs such as vinorelbine, docetaxel and paclitaxel.  
 Ep-CAM (epithelial cell adhesion molecule) is highly expressed in colorectal, non-small cell 
lung and prostatic cancer and so on. Edrecolomab, came from murine and transformed into 
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human chimeric construct, is a manual antibody for Ep-CAM. The clinical testing showed 
the chimeric construct increased mononuclear cell-mediated ADCC and prolonged half-life 
than the murine mAb. In addition, it develops no human anti-mouse antibodies (Hartung et 
al., 2005). 
5.2 Targets in lymphomas 
The mAb direct against human B cell lymphoma–associated antigen have shown enormous 
power on clearance circulating tumor cells with rare objective clinical responses. The 
mechanisms underlying responses to these mAb are complex and have not been completely 
elucidated now, while the main mechanisms could include ADCC and disturbance 
transductional signals. Another target, CD52, a glycopeptides exists on T and B 
lymphocytes, has been tested as a target for mAb in the treatment of numerous lymphomas 
which decreased the response from allogeneic transplant grafts.  
5.3 Toxicity of mAb 
mAb are paid more attention as the clinical tests were shown with less toxicity than the 
normal cytotoxic chemotherapy and radiotherapy. But cytotoxic always emergence through 
two ways, one is mechanism-dependent and the other is mechanism-independent. 
Mechanism-independent occur for the mAb proteins produced by the xenogeneic gene. The 
primary toxicity of mAbs is mechanism-dependent toxicity that exaggerated pharmacology 
of blocking or enhancing the activities of the target cells or tissues target molecule. Toxicity 
is also resulted from binding to the target in normal tissues other than cancer tissues alone. 
Treatment with cetuximab can cause the skin toxicity (acneiform rash) and the cardiotoxicity 
observed with trastuzumab due to skin and cardiac muscle respectively expressing the same 
target antigens.  
 
 
Fig. 4. Targets in solid tumors and lymphomas 
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5.4 Further exploration 
Nowadays mAbs have achieved significantly success compared with the disappointment of 
failure in decades ago. Despite these accomplishments, the clinical response remains, such 
as the toxicity on the normal cells. Regardless of these challenges, each new anticancer mAb 
approved represents more choice and potential benefit to patients. With the development of 
biotechnology, the efficient and safe mAb for cancer patients may be produced. “We have a 
long way to go before the story is finished,” says Winter (Gura, 2002). 
6. Viral vector for gene delivery 
Cancer is a multigenic disorder involving activation of oncogenes and inactivation of 
suppressor genes. Many data has suggested that cancer can be arrested or reversed by 
treatment with gene transfer vectors that carrying therapeutic genes. The vectors used for 
gene therapy include viral or non-viral vectors. Viruses have been the most common vectors 
for gene therapy and about 70% of gene therapy clinical trials use viral vectors. The main 
viral vectors used in clinic include retroviruses, adenovirus, adeno-associated virus, 
herpesvirus and poxvirus.  
Retrovirus is an enveloped RNA virus. The genome of retrovirus contains two identical 
single-stranded RNAs about 7-10 kb. There are three open reading frames, gap, pol and env, 
and two long terminal repeats (LTRs) in retroviral genome (Baum et al., 2006). Replication-
defective retroviral vectors (RDR) lack genes required for self-replication and the capability 
of cell-to-cell spreading. RDR vectors have used to deliver therapeutic genes into 
immunodeficiency disease. Replication-competent retrovirus (RCR) vectors can duplicate in 
dividing cells and result cell lysis. Retrovirus may randomly integrate to host genome and 
results insertional mutagenesis. Many methods has been explored to improve the safety of 
RCR vectors, such as using tissue-specific regulatory sequences replace the viral promoter 
elements; using inducible regulatory sequences to control transcription.  
Lentivirus is a kind of slow viruses of the Retroviridae family. In contrast with simple 
retrovirus, lentivirus has evolved the ability to infect nondividing cells (Cockrell and Kafri, 
2007). Recently, the inducible tet-on/off lentivirus expression system has been structured by 
researchers. Using this system, researchers can control gene expression, so this system is a 
powerful tool to research transgene expression.  
Adenovirus is a linear, double-stranded and non-enveloped DNA virus. The genome of 
adenovirus is about 36 kb. Over 50 serotypes of human Adenovirus have been identified, 
among which Ad5 is the most commonly used vector. Unlike the retrovirus, adenovirus 
genomes do not integrate into the host chromosome, so it is a safe vector for transient 
transgene expression. Replication-defective adenoviruses have been used to transfer tumor-
suppressor genes, anti-angiogenesis genes, immunostimulatory genes, prodrug-activating 
genes. In 2004, replication-deficient recombinant adenovirus (Ad)-p53 was approved to use 
for head and neck squamous cell carcinoma (HNSCC) by China’s State Food and Drug 
Administration. In china another cancer gene therapy agentia Ad-endostatin (E10A) has 
been finished the classⅠ clinical trial for solid cancers and no dose-limiting toxicity was 
developed (Lin et al., 2007).  
Adeno-Associated Virus (AAV) is a small, nonenveloped DNA virus. Its genome is a linear 
single-stranded DNA of 4.7 kb. AAV produces infection only in the presence of adenovirus 
or herpesvirus. In the absence of helper virus, AAV can set up latency by integrating into 
chromosome 19q13.4 (Lai et al., 2002). AAV vectors have successfully delivered targeting 
www.intechopen.com
 
Targets in Gene Therapy 
 
180 
genes into varieties of dividing and quiescent cells, including in the muscle, liver, lung, 
brain, eye, retina and heart. The therapeutic genes that AAV vectors contain are no more 
than 5kb. Researchers invent a new AAV vectors system which uses head-to-tail 
heterodimers of the two rAAV vectors form via recombination in the ITRs, which can 
improves the packaging capacity of AAV vectors to 10 kb. This vector has been successfully 
used for gene expression in the retina, lung and muscle diseases. 
Herpes Simplex Virus (HSV) is double-strand DNA virus. HSV-1 is the common vector in 
gene therapy. The genome of HSV includes long and short unique regions, each flanked by 
inverted repeats. The neurotropic ability of HSV makes this vector for the design of gene 
therapies that target cancers of the CNS (Shen and Nemunaitis, 2006). The replication-
defective HSV vector lacks one or several essential immediate-early (IE) genes. Some 
researchers have used replication-defective HSV vector with suicide genes, such as 
thymidine kinase (TK) gene or cytosine deaminase (CD), treat CNS malignant tumors. 
Conditionally replicating HSV vector delete some genes for virus replication, but this vector 
can duplicate in cancer cells where it gains the enzymes of replication. This vector is an 
oncolytic HSV vector and has widely used to treat the squamous cancers in head and neck, 
malignant glioma, colorectal cancer, pancreatic cancer and prostate cancer.      
Poxvirus is a kind of complex DNA virus. The genome is linear double-stranded DNA and 
the size of the different poxvirus species is variable from 130kb to 160kb. The dsDNA 
molecule contains the open reading frame (ORF) and the inverted terminal repeats (ITRs) in 
the terminal regions of the genome (Lefkowitz et al., 2006). Poxvirus as a transgene vector 
with tumor-associated antigens or tumor-specific antigens has been used in cancer therapy, 
which can improve hose anti-cancer ability. 
7. Nonviral vector for gene delivery 
During the past two decades, gene therapy has gained rapid development as a promising 
therapeutic modality for the treatment of genetic and acquired disorders (Al-Dosari and 
Gao, 2009). However, the rate-limiting step is lack of a suitable vector for gene delivery. 
Although viral vectors are attractive in initial research due to its high efficiency, nonviral 
gene-delivery carriers have gained increasing attention in recent years because their safety 
and easy preparation advantages over viral vectors. 
Nonviral vectors for gene therapy have been categorized as expression vector and delivery 
vector. Among the nonviral vectors, the most widely used expression vector is plasmid 
DNA. Methods of nonviral gene delivery contained direct injection of naked plasmid DNA, 
physical and chemical approaches (Gao et al., 2007). Physical approaches employing 
mechanical (particle bombardment or gene gun), electric (electroporation), ultrasonic, or 
hydrodynamic (hydrodynamic gene transfer) have been explored in recent years. Chemical 
methods mediate gene uptake by membrane fusion and/or receptor-mediated endocytosis. 
Chemical vectors such as cationic lipids and cationic polymers form condense complexes 
with negatively charged DNA through electrostatic interactions (Al-Dosari and Gao, 2009; 
Ohlfest et al., 2005).   
7.1 Nonviral therapeutics in clinical trials 
Although adenoviral- and retroviral-mediated transfections are currently the most widely 
used strategies for gene therapy in clinical trials, there are more than 400 clinical trials using 
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nonviral vectors so far (www.wiley.co.uk/genmed/clinical). Lipid and polymer-mediated 
gene delivery has been used to successfully target both genetic diseases as well as cancer. 
With extensive effort being put into designing nonviral vectors with higher gene transfer 
efficiency, synthetic gene carriers may become superior to viral analogues in clinical trials in 
the near future. 
 
 
Fig. 5. Vectors used in gene therapy 
8. Future direction and challenge   
Single targeted cancer therapy can not be expected to yield optimal outcomes as 
tumorigenesis is a multistep process and its molecular pathogenesis is not linked to the 
defect of a single target. Therefore, multi-targeted therapy through the combination of 
agents targeting distinct molecules might be the goals for targeting therapy in the near 
future. This could overcome the issues of tumour heterogeneity and maintain the selectivity 
of treatment at the same time. In addition, monotherapy is further evolving to single 
inhibitor which can target several molecules simultaneously. It seems promising that with 
our better understanding of tumor biology, more efficacious combinations for targeted 
therapy will emerge in the immediate future (Imai and Takaoka, 2006). 
Another new aspect of cancer-targeted therapy is employing cancer stem cells as the target. 
It was reported that mTOR inhibition by rapamycin selectively eliminated leukaemic stem 
cells without affecting normal haematopoietic stem cells (Zhang et al., 2006). Therefore, 
targeting abnormal signalling pathway in cancer stem cells might offer an effective 
approach for targeting therapies. Besides, it is of great importance to identify predictive 
markers for the response to targeted therapy (Swain, 2011). Beyond its obvious clinical 
benefits for cancer patients, the identification of predictive markers can also reduce the costs 
of cancer treatments (Warren et al., 2008).  
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